
Banker joins Lilly Board
pharmafile | October 25, 2013 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | jackson tai, lilly
Eli Lilly has appointed ex-investment banker Jackson Tai to its Board to serve on the Audit and Finance Committee from November.
Tai is currently a non-executive director of The Bank of China Limited, Singapore Airlines, NYSE Euronext, MasterCard Incorporated, and Royal Philips NV.
From 2002 to 2007 he was vice chairman and chief executive of both DBS Group Holdings and DBS Bank, one of the largest financial services groups in Asia.
I am delighted to welcome Jack Tai to the Lilly board,” said John Lechleiter, Lilly’s chairman, president and chief executive. “Mr Tai brings to the Lilly board extensive experience in international business and finance, including serving as the CEO of a major multinational financial institution and as a board member of several leading global companies.”
Prior to his appointment at DBS Tai was an investment banker for 25 years with J.P. Morgan.
Related Content
NICE RECOMMENDS LILLY’S TIRZEPATIDE (MOUNJARO ®▼) FOR MANAGING OVERWEIGHT AND OBESITY IN FINAL DRAFT GUIDANCE
BASINGSTOKE, 5th December 2024 – Eli Lilly and Company announced today that the National Institute …

Lilly’s COVID-19 drug has EUA revoked in favour of combination therapy
The FDA have revoked Emergency Use Authorization (EUA) of Eli Lilly’s bamlanivimab drug for the …

Lilly’s ulcerative colitis treatment meets all key endpoints in Phase III trial
Eli Lilly’s mirikizumab treatment for ulcerative colitis (UC) patients has met the primary endpoints and …






